Equities research analysts expect Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to report $53.97 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Eagle Pharmaceuticals’ earnings. The lowest sales estimate is $52.90 million and the highest is $55.04 million. Eagle Pharmaceuticals reported sales of $46.63 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 15.7%. The firm is expected to issue its next earnings results on Thursday, May 9th.
According to Zacks, analysts expect that Eagle Pharmaceuticals will report full-year sales of $231.26 million for the current fiscal year, with estimates ranging from $219.80 million to $242.72 million. For the next fiscal year, analysts anticipate that the company will post sales of $229.20 million, with estimates ranging from $209.70 million to $248.70 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Eagle Pharmaceuticals.
Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings data on Thursday, February 28th. The specialty pharmaceutical company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.16 by $0.04. The company had revenue of $56.05 million during the quarter, compared to the consensus estimate of $54.17 million. Eagle Pharmaceuticals had a net margin of 14.96% and a return on equity of 17.76%. The company’s quarterly revenue was up 19.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.05 EPS.
Several analysts recently issued reports on EGRX shares. BidaskClub downgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 7th. Royal Bank of Canada set a $66.00 price target on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, March 1st. Zacks Investment Research raised shares of Eagle Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $51.00 price target for the company in a research report on Monday, December 17th. Finally, ValuEngine raised shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, March 1st. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $65.50.
In other news, CEO Scott Tarriff sold 30,085 shares of Eagle Pharmaceuticals stock in a transaction on Friday, February 1st. The stock was sold at an average price of $41.54, for a total transaction of $1,249,730.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 86,082 shares of company stock worth $3,746,371. Company insiders own 28.20% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. California Public Employees Retirement System purchased a new stake in Eagle Pharmaceuticals in the 2nd quarter worth about $208,000. Bank of New York Mellon Corp increased its holdings in Eagle Pharmaceuticals by 4.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 153,716 shares of the specialty pharmaceutical company’s stock worth $11,630,000 after acquiring an additional 6,310 shares during the last quarter. Texas Permanent School Fund increased its holdings in Eagle Pharmaceuticals by 30.5% in the 3rd quarter. Texas Permanent School Fund now owns 7,010 shares of the specialty pharmaceutical company’s stock worth $486,000 after acquiring an additional 1,638 shares during the last quarter. Arizona State Retirement System increased its holdings in Eagle Pharmaceuticals by 33.7% in the 3rd quarter. Arizona State Retirement System now owns 16,162 shares of the specialty pharmaceutical company’s stock worth $1,121,000 after acquiring an additional 4,071 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in Eagle Pharmaceuticals in the 3rd quarter worth about $115,000. Institutional investors own 92.54% of the company’s stock.
Shares of EGRX stock traded down $0.31 during trading hours on Friday, hitting $47.02. 188,014 shares of the company were exchanged, compared to its average volume of 214,628. The company has a market cap of $659.02 million, a price-to-earnings ratio of 22.50 and a beta of 1.73. Eagle Pharmaceuticals has a fifty-two week low of $36.03 and a fifty-two week high of $85.66. The company has a quick ratio of 3.92, a current ratio of 4.13 and a debt-to-equity ratio of 0.24.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
Recommended Story: What is the yield curve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.